G.A. GARINA¹, A.A. KAMALOVA^1, 2, I.KH. VALEEVA¹, G.M. YAKUPOVA³, A.R. KHABIBULLINA²

 ¹Kazan State Medical University, Kazan

²Children’s Republican Clinical Hospital, Kazan

³Republican Children’s Clinical Hospital, Ufa

  Contact details:

Garina G.A. — post-graduate student of the Department оf Hospital Pediatrics

Address: 49 Butlerov St., 420012 Kazan, Russian Federation, tel.: +7-987-008-38-69, e-mail: galinagalina.gala@yandex.ru

Determination of fecal calgranulin is a potential alternative to ileocolonoscopy in diagnosing and monitoring inflammatory bowel diseases (IBD).

The purpose was to study the diagnostic value of fecal calgranulin in Crohn’s disease and ulcerative colitis in children.

Material and methods. The study included 118 patients with inflammatory bowel diseases (IBD) and 30 conditionally healthy children. The average age was 14 years (Q1–Q3 — 11–16). In all children, the level of fecal calgranulin and calprotectin was determined by ELISA (Cloud-clone Corp., USA, unit of measurement — pg/ml), depending on the indicators of clinical, laboratory, endoscopic and histological activity of the disease.

Results. Calgranulin levels were statistically significantly higher in ulcerative colitis and Crohn’s disease than in children from the control group. When comparing the calgranulin concentration depending on the clinical activity of Crohn’s disease, it was found that the biomarker level was higher in the active stage (Me — 275.40; Q1–Q3 — 217.91–413.87 pg/ml) than in the inactive stage (Me — 67.36; 54.68–89.08 pg/ml), p ˂ 0.05. Also, the calgranulin level was higher in the endoscopically active form of Crohn’s disease (Me — 364.11; Q1–Q3 — 215.77–510.1 pg/ml) than in endoscopic remission (Me — 49.16; Q1–Q3 — 44.89–54.14 pg/ml), p ˂ 0.05. Correlation analysis of calgranulin concentration with laboratory parameters did not reveal statistically significant relationships.

Key words: calgranulin, children, inflammatory bowel diseases.

REFERENCES

1. Liu F., Lee S.A., Riordan S.M., Zhang L., Zhu L. global studies of using fecal biomarkers in predicting relapse in inflammatory bowel disease. Front. Med. (Lausanne), 2020, vol. 7. 580803. DOI: 10.3389/fmed.2020.580803
2. Lopez R.N., Leach S.T., Lemberg D.A., Duvoisin G., Gearry R.B., Day A.S. Fecal biomarkers in inflammatory bowel disease. J. Gastroenterol. Hepatol, 2017, vol. 32, pp. 577–582. DOI: 10.1111/jgh.13611
3. Laharie D., Mesli S., El Hajbi F., Chabrun E., Chanteloup E., Capdepont M. et al. Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol. Ther, 2011, vol. 34, pp. 462–469. DOI: 10.1111/j.1365–2036.2011.04778.x
4. Kopylov U., Yung D.E., Engel T., Avni T., Battat R., Ben-Horin S. et al. Fecal calprotectin for the prediction of small-bowel Crohn’s disease by capsule endoscopy: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol, 2016, vol. 28 (10), pp. 1137–1144. DOI: 10.1097/MEG.0000000000000692
5. Witarto B.S., Visuddho V., Witarto A.P., Sampurna M.T.A., Irzaldy A. Performance of fecal S100A12 as a novel non-invasive diagnostic biomarker for pediatric inflammatory bowel disease: a systematic review and meta-analysis. J. Pediatr. (Rio J), 2023, vol. 99 (5), pp. 432–442. DOI: 10.1016/j.jped.2023.03.002
6. Heida A., van de Vijver E., van Ravenzwaaij D., van Biervliet S., Hummel T.Z., Yuksel Z. et al. CACATU consortium. Predicting inflammatory bowel disease in children with abdominal pain and diarrhoea: calgranulin-C versus calprotectin stool tests. Arch. Dis. Child, 2018, vol. 103 (6), pp. 565–571. DOI: 10.1136/archdischild-2017-314081
7. Klinicheskie rekomendatsii Ministerstva zdravookhraneniya RF po yazvennomu kolitu u detey (ID 391). Utverzhdeny Ministerstvom zdravookhraneniya RF v 2023 g. Odobreny nauchno-prakticheskim sovetom Minzdrava RF, 2023 [Clinical guidelines of the Ministry of Health of the Russian Federation on ulcerative colitis in children (ID 391). Approved by the Ministry of Health of the Russian Federation in 2023. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation, 2023]. Pp. 14–20.
8. Klinicheskie rekomendatsii Ministerstva zdravookhraneniya RF Bolezn’ Krona 2023(ID 682). Utverzhdeny Ministerstvom zdravookhraneniya RF v 2023 g. Odobreny nauchno-prakticheskim sovetom Minzdrava RF, 2023 [Clinical guidelines of the Ministry of Health of the Russian Federation Crohn’s disease 2023 (ID 682). Approved by the Ministry of Health of the Russian Federation in 2023. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation, 2023]. P. 15.
9. Koutroumpakis E., Katsanos K.H. Implementation of the simple endoscopic activity score in crohn’s disease. Saudi J. Gastroenterol, 2016, vol. 22 (3), pp. 183–191. DOI: 10.4103/1319-3767.182455
10. Vespa E., D’Amico F., Sollai M., Allocca M., Furfaro F., Zilli A. et al. Histological scores in patients with inflammatory bowel diseases: the state of the art. J. Clin. Med, 2022, vol. 11 (4), p. 939. DOI: 10.3390/jcm11040939
11. Leach S.T., Yang Z., Messina I. et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand. J. Gastroenterol, 2007, vol. 42, pp. 1321–1331. DOI: 10.1080/00365520701416709
12. Heida A., van de Vijver E., van Ravenzwaaij D., van Biervliet S., Hummel T.Z., Yuksel Z. et al. CACATU consortium. Predicting inflammatory bowel disease in children with abdominal pain and diarrhoea: calgranulin-C versus calprotectin stool tests. Arch. Dis. Child, 2018, vol. 103 (6), pp. 565–571. DOI: 10.1136/archdischild-2017-314081